Back
Results - Announcements
Themis Medicare Ltd consolidated sales up 13.63% on year in Q2FY2026, net profit jumped 176.83%
13-Aug-2026, 04:23
Themis Medicare Ltd share price declined by 4.73% to Rs 107.65. The Company's net profit saw a strong growth of 176.83% to Rs 24.61 crore, while revenue from operations gained 13.63% to Rs 86.96 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.61%. It has marginally improved by 0.97% over last one week and heading higher by 11.17% in last one month while the market capitalization of Themis Medicare Ltd has softened by 4.44% and 9.91% in the same period respectively. Profit before tax (PBT) of Themis Medicare Ltd stood at Rs 38.6 crore in Q2 FY26, tanking 374.54% year-on-year, and jumping 326.05% quarter-on-quarter. EBITDA came in at Rs 53 crore, surging by 374.33% YoY and tumbling by 59444.44% sequentially. Total expenses witnessed a sharp rise of 88.30% to Rs 141.92 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 17.63 crore, witnessing a sharp rise of 23.55% YoY, while employee benefits expense was at Rs 22.18 crore, inching up 5.32% YoY. For the TTM ended FY26, revenue from operations inched higher 6.22% to Rs 405.51 crore, while net profit plunged by 31.46% to Rs 29.83 crore, compared to previous TTM. EBITDA surged by 4343% to Rs 44.38 crore, and PBT collapsed by 25.77% to Rs 39.67 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 34.71 crore in FY26, as against Rs 22.09 crore in FY25. Themis Medicare Ltd gained 1.27% in last one year, outperforming the benchmark BSE Sensex which has slipped by 2.83% during the same period.
Themis Medicare Ltd share price declined by 4.73% to Rs 107.65. The Company's net profit saw a strong growth of 176.83% to Rs 24.61 crore, while revenue from operations gained 13.63% to Rs 86.96 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.61%. It has marginally improved by 0.97% over last one week and heading higher by 11.17% in last one month while the market capitalization of Themis Medicare Ltd has softened by 4.44% and 9.91% in the same period respectively. Profit before tax (PBT) of Themis Medicare Ltd stood at Rs 38.6 crore in Q2 FY26, tanking 374.54% year-on-year, and jumping 326.05% quarter-on-quarter. EBITDA came in at Rs 53 crore, surging by 374.33% YoY and tumbling by 59444.44% sequentially. Total expenses witnessed a sharp rise of 88.30% to Rs 141.92 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 17.63 crore, witnessing a sharp rise of 23.55% YoY, while employee benefits expense was at Rs 22.18 crore, inching up 5.32% YoY. For the TTM ended FY26, revenue from operations inched higher 6.22% to Rs 405.51 crore, while net profit plunged by 31.46% to Rs 29.83 crore, compared to previous TTM. EBITDA surged by 4343% to Rs 44.38 crore, and PBT collapsed by 25.77% to Rs 39.67 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 34.71 crore in FY26, as against Rs 22.09 crore in FY25. Themis Medicare Ltd gained 1.27% in last one year, outperforming the benchmark BSE Sensex which has slipped by 2.83% during the same period.